Markets:

Overview

News

Currencies

International

Treasuries

Awakn Life Sciences Corp (OP:AWKNF)

0.0650 UNCHANGED

Last Price Updated: 3:11 PM EST, Dec 13, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Awakn Life Sciences Corp

< Previous 1 2 3 4 5 Next >

Awakn Life Sciences Seeks To Treat Addictions: Gambling, Binge Eating And Compulsive Sexual Behavior ↗

March 28, 2022

Awakn Life Sciences (OTC: AWKNF) is not only going after alcoholism but also binge eating disorder, compulsive sexual behavior and even Internet gaming disorder.

Via Benzinga

This Ketamine-Assisted Therapy Company Is Developing New Ways To Treat Alcohol Addiction ↗

March 24, 2022

Picture credit: Martin Sanchez on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.

Via Benzinga

Psychedelic And Cannabis Drug Stocks Continue Advance ↗

February 13, 2022

This article updates the performances of 16 clinical-stage psychedelic and marijuana drug companies researching the treatment of a wide variety of mental illnesses.

Via Talk Markets

Mindset Pharma, Cybin Among Top Psychedelic Movers Of Today ↗

February 08, 2022

GAINERS: Awakn Life Sciences (OTC:AWKNF) shares closed up 3.51% at $1.62

Via Benzinga

Mind Medicine, Allied Among Top Psychedelic Movers Of Today ↗

February 02, 2022

GAINERS: Small Pharma (OTC:DMTTF) shares closed up 5.04% at $0.17

Via Benzinga

Awakn Life Sciences: Wake Up To The Huge Potential ↗

November 01, 2021

The private global addiction treatment industry is currently valued at US$17.5 billion per year and forecast to increase to US$31.5 billion per year by 2027.

Via Talk Markets

Has A Sugar Daddy Emerged In The Psychedelic Drug Industry? ↗

January 31, 2022

One very large drug multinational has already been active in writing checks to finance drug development in the psychedelic drug industry.

Via Talk Markets

The Psychedelic & Marijuana Drug Stocks Index Dropped -30% In January ↗

January 30, 2022

This article updates the performances of 16 clinical-stage psychedelic and marijuana drug companies researching the treatment of a wide variety of mental illnesses.

Via Talk Markets

Mind Medicine, Small Pharma Among Top Psychedelic Movers Of Today ↗

January 27, 2022

GAINERS: Mindset Pharma (OTC:MSSTF) shares closed up 6.29% at $0.49

Via Benzinga

Psychedelic Stock Gainers And Losers From January 24, 2022 ↗

January 24, 2022

GAINERS: Field Trip Health (NASDAQ:

Via Benzinga

Psychedelic Stock Gainers And Losers From January 21, 2022 ↗

January 21, 2022

GAINERS: GH Research (NASDAQ:

Via Benzinga

Psychedelic Stock Gainers And Losers From January 20, 2022 ↗

January 20, 2022

GAINERS: Small Pharma (OTC:

Via Benzinga

Revive Therapeutics, GH Research Among Top Psychedelic Movers Of Today ↗

January 19, 2022

GAINERS: Revive Therapeutics (OTC:

Via Benzinga

Psychedelic Stock Gainers And Losers From January 18, 2022 ↗

January 18, 2022

GAINERS: Cybin (AMEX:

Via Benzinga

Psyched: Delix Raises $30M, New Ketamine Study For Alcohol Use Disorder, FDA Approves Ketamine Trial For ALS ↗

January 18, 2022

New Awakn Study Shows Ketamine Has Potential To Treat Alcoholism Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB:

Via Benzinga

Ketamine Therapy Shows Potential In Treatment Of Alcohol Use Disorder, New Study Finds ↗

January 11, 2022

Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB:AWKNF) publis...

Via Benzinga

The Year In Review For Psychedelic Drug Stocks: 2021 ↗

December 21, 2021

2021 was two different

Via Talk Markets

Marijuana & Psychedelic Compounds-Based Drug Stocks Now Down -16% YTD ↗

December 17, 2021

A look at which index has done the best so far in December: the Marijuana Drug Stocks Index or the Psychedelic Compounds-Based Drug Stocks Index.

Via Talk Markets

AWKNF: A Psychedelic's Stock Exhibiting Recent Price Appreciation ↗

November 24, 2021

Awakn Health Sciences Corp's trading pattern over the past 10-day time span is an egregious example of a psychedelic stock that has exhibited recent price appreciation coupled with a surge in average...

Via Talk Markets

Psychedelic Drug Stocks Continued To Decline Last Week ↗

November 21, 2021

The 12 constituents in our Pure-Play Psychedelic Compounds-Based Drug Stocks Index declined -5.7% last week; it's now -16.1% so far in November.

Via Talk Markets

New Options to Treat Alcohol Use Disorder

November 15, 2021

New Options to Treat Alcohol Use Disorder

Via News Direct

Psychedelic Drug Stocks Have Plunged -10.6%, On Average, So Far In November ↗

November 14, 2021

Our Pure-Play Psychedelic Compounds-Based Drug Stocks Index has declined -10.6% in the last 2 weeks; it's still up +7.8% since the end of September.

Via Talk Markets

BioMedNewsBreaks – Mind Cure Health Inc.’s (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) iSTRYM Opening New Revenue Source, Helping Fuel Further Growth, Expansion

November 12, 2021

Via Investor Brand Network

Compass Pathways Phase II Results: A Disappointment For Some, An Opportunity For Others ↗

November 11, 2021

Compass Pathways reported

Via Talk Markets

Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) Growth Strategy Moves Forward with Awakn Life Sciences (NEO: AWKN) (OTCQB: AWKNF) Partnership for Ketamine-Assisted Psychotherapy Distribution

November 04, 2021

Via Investor Brand Network

Psyched: MindMed's MDMA Program For Autism, Small Pharma's New Patent, NovaMentis' Orphan Drug Designation ↗

November 01, 2021

The Week In Psychedelics:

Via Benzinga

Topics Intellectual Property

PsychedelicNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) Enters Strategic LOI to Distribute Ketamine Protocol

October 28, 2021

Via Investor Brand Network

MINDCURE Signs LOI with Awakn Life Sciences to Distribute Ketamine Protocol for Alcohol Use Disorder into Clinics Across United States and Canada through iSTRYM, MINDCURE’s Digital Therapeutics Platform

October 28, 2021

Vancouver, BC – October 28, 2021 – Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) (“MINDCURE” or the “Company”), a leader in advanced proprietary technology and research for psychedelics,...

Via FinancialNewsMedia

Psyched: British PM Considers Psychedelics, New Partnership To Study Psilocybin For Autism, Compass Gets Another Patent ↗

October 26, 2021

The Week In Psychedelics

Via Benzinga

Psychedelic Stocks Rebounded 9% Last Week; Small Pharma Was Up 148% ↗

October 24, 2021

The Psychedelic Compounds-Based Drug Stocks Index was up +8.9% last week albeit still down -18.5% YTD.

Via Talk Markets

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.